Join us   Log in  

PHARMASPIRE - Volume 12, Issue 2, April - June, 2020

Pages: 61-71
Print Article   Download XML  Download PDF

Development and characterization of in situ gel of embelin for the management of Huntington’s disease

Author: Himani Kapahi , Ajay Kumar , Navjot Kaur Sandhu , Puneet Bansal , Neeraj Mishra

Category: Pharmaceutics


Aim: This study aims to investigate the in-situ gel for the enhancement of brain drug concentration of embelin for the effective management of Huntington’s disease. Preparation situ gel was prepared by cold method. Optimization: Prepared in situ gel formulation was optimized and characterized by various parameters such as clarity, gelation temperature, gelation time, gel strength, rheological studies, and mucoadhesive force. Gelation time and temperature, mucoadhesive strength of optimized formulation F3 was found to be 30 s, 32–34°C, 1891 dyne/cm2 . Optimized formulation was also evaluated by in vitro drug release and in vivo studies such as behavioral parameter, biochemical estimation, and neurological estimations. Results: By these parameters, optimized formulation was found to be suitable for the management of Huntington’s Disease by nasal route because it bypasses the blood-brain barrier by decreasing oxidative stress.

Keywords: Neurodegenerative disorder, in situ gel, Huntington’s disease, nasal delivery, thermoreversible polymers


1. Palmer S, Li J, Wang ZJ, McKeown MJ. Joint amplitude and connectivity compensatory mechanisms in Parkinson’s disease. Neuroscience 2010;166:1110-8.

2. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson’s disease: What have we learned from pesticide-induced animal models? Trends Pharmacol Sci 2009;30:475-83.

3. Nance MA, Myers RH. Juvenile onset Huntington’s disease-clinical and research perspectives. Ment Retard Dev Disabil Res Rev 2001;7:153-7.

4. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-84.

5. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington’s disease. Nat Rev Neurosci 2004;5:373-84.

6. Teunissen C, Steinbusch HW, Angevaren M, Appels M, de Bruijn C, Prickaerts J, et al. Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: Disturbed walking pattern and spatial orientation. Neuroscience 2001;105:153-67.

7. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: A PET study. Brain 2003;126:1127-35.

8. Paleacu D. Tetrabenazine in the treatment of Huntington’s disease. Neuropsychiatr Dis Treat 2007;3:545.

9. Frank S. Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010;6:657-65.

10. Ghori MU, Mahdi MH, Smith AM, Conway BR. Nasal drug delivery systems: An overview. Am J Pharmacol Sci 2015;3:110-9.

11. Dhadde SB, Nagakannan V, Roopesh M, Kumar SR, Thippeswamy BS, Veerapur VP, et al. Effect of embelin against 3-nitropropionic acid-induced Huntington’s disease in rats. Biomed Pharmacother 2016;77:52-8.

12. Thippeswamy B, Nagakannan P, Shivasharan BD, Mahendran S, Veerapur VP, Badami S. Protective effect of embelin from Embelia ribes Burm. Against transient global ischemia-induced brain damage in rats. Neurotox Res 2011;20:379-86.

13. Mahendran S, Thippeswamy BS, Veerapur VP, Badami S. Anticonvulsant activity of embelin isolated from Embelia ribes. Phytomedicine 2011;18:186-8.

14. Rao GV, Sateesh K, Mujahidul I, Saber EM. Folk medicines for anticancer therapy-a current status. Cancer Ther 2008;6:913-21.

15. Surveswaran S, Cai YZ, Corke H, Sun M. Systematic evaluation of natural phenolic antioxidants from 133 Indian medicinal plants. Food Chem 2007;102:938-53.

16. Bhandari U, Ansari MN. Protective effect of aqueous extract of Embelia ribes Burm fruits in middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Indian J Pharmacol 2008;40:215.

17. Johal HS, Garg T, Rath G, Goyal AK. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv 2016;23:550-63.

18. Joshi R, Kamat J, Mukherjee T. Free radical scavenging reactions and antioxidant activity of embelin: Biochemical and pulse radiolytic studies. Chem Biol Interact 2007;167:125-34.

19. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv 2015;22:1027-42.

20. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst 2014;31:89-119.

21. Garg T, Goyal AK. Biomaterial-based scaffolds-current status and future directions. Expert Opin Drug Deliv 2014;11:767-89.

22. Marttin E, Merkus FW, Verhoef JC, Schipper NG. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13-38.

23. Critchley H, Davis SS, Farraj NF, Illum L. Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J Pharm Pharmacol 1994;46:651-6.

24. Garg T, Singh O, Arora S, Murthy R. Scaffold: A novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 2012;29:1-63.

25. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: An excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst 2013;30:369-409.

26. Bhalerao A, Lonkar SL, Deshkar SS, Shirolkar SV, Deshpande AD. Nasal mucoadhesive in situ gel of ondansetron hydrochloride. Indian J Pharm Sci 2009;71:711.

27. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, et al. In situ evidence for DNA fragmentation in Huntington’s disease striatum and Alzheimer’s disease temporal lobes. Neuroreport 1995;6:1053-7.

28. Ibrahim ES, Ismail S, Fetih G, Shaaban O, Hassanein K, Abdellah NH. Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application. Acta Pharm 2012;62:59-70.

29. Choi HG, Jung JH, Ryu JM, Yoon SJ, Oh YK. Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm 1998;165:33-44.

30. Yong CS, Choi JS, Quan QZ, Rhee JD, Kim CK, Lim SJ, et al. Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. Int J Pharm 2001;226:195-205.

31. Gilbert JC, Washingtona C, Daviesa MC, Hadgraftb J. The effect of solutes and polymers on the gelation properties of pluronic F-127 solutions for controlled drug delivery. J Control Release 1987;5:113-8.

32. Sharma S, Lohan S, Murthy R. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 2014;40:869-78.

33. Kalonia H, Kumar P, Kumar A, Nehru B. Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. Inflammopharmacology 2009;17:211-9.

34. Khan A, Jamwal S, Bijjem KR, Prakash A, Kumar P. Neuroprotective effect of hemeoxygenase-1/glycogen synthase kinase-3β modulators in 3-nitropropionic acid-induced neurotoxicity in rats. Neuroscience 2015;287:66-77.

35. Wills E. Mechanisms of lipid peroxide formation in animal tissues. Biochem J 1966;99:667.

36. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15 N] nitrate in biological fluids. Anal Biochem 1982;126:131-8.

37. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.

38. Patel BA, Arundell M, Parker KH, Yeoman MS, O’Hare D. Simple and rapid determination of serotonin and catecholamines in biological tissue using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005;818:269-76.

39. Borlongan CV, Koutouzis TK, Sanberg PR. 3-Nitropropionic acid animal model and Huntington’s disease. Neurosci Biobehav Rev 1997;21:289-93.

40. Shivasharan B, Nagakannan P, Thippeswamy BS, Veerapur VP, Bansal P, Unnikrishnan MK. Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington’s disease in rats. Drug Chem Toxicol 2013;36:466-73.

41. Martyniuk CJ, Fang B, Koomen JM, Gavin T, Zhang L, Barber DS, et al. Molecular mechanism of glyceraldehyde-3-phosphate dehydrogenase inactivation by α, β-unsaturated carbonyl derivatives. Chem Res Toxicol 2011;24:2302-11.

42. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. J Neurosci 1999;19:1484-91